Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 03 04:00PM ET
131.35
Dollar change
-2.16
Percentage change
-1.62
%
Index- P/E- EPS (ttm)-8.10 Insider Own0.82% Shs Outstand59.76M Perf Week0.38%
Market Cap7.85B Forward P/E- EPS next Y-3.82 Insider Trans0.00% Shs Float59.27M Perf Month4.85%
Income-462.37M PEG- EPS next Q-1.35 Inst Own105.10% Short Float6.03% Perf Quarter9.92%
Sales354.45M P/S22.15 EPS this Y15.50% Inst Trans5.42% Short Ratio5.38 Perf Half Y-2.31%
Book/sh-1.82 P/B- EPS next Y49.66% ROA-43.11% Short Interest3.57M Perf Year26.24%
Cash/sh11.68 P/C11.24 EPS next 5Y38.10% ROE-867.62% 52W Range101.43 - 161.00 Perf YTD4.29%
Dividend Est.- P/FCF- EPS past 5Y-19.87% ROI-171.47% 52W High-18.42% Beta0.65
Dividend TTM- Quick Ratio0.84 Sales past 5Y182.00% Gross Margin80.51% 52W Low29.50% ATR (14)4.91
Dividend Ex-Date- Current Ratio1.16 EPS Y/Y TTM28.89% Oper. Margin-96.61% RSI (14)52.87 Volatility3.32% 4.21%
Employees- Debt/Eq- Sales Y/Y TTM117.15% Profit Margin-130.45% Recom1.00 Target Price195.25
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q39.60% Payout- Rel Volume0.41 Prev Close133.51
Sales Surprise-20.43% EPS Surprise-6.35% Sales Q/Q21.59% EarningsNov 14 AMC Avg Volume664.61K Price131.35
SMA202.33% SMA50-0.14% SMA200-3.65% Trades Volume270,729 Change-1.62%
Date Action Analyst Rating Change Price Target Change
Sep-05-24Upgrade Oppenheimer Perform → Outperform $180
Jun-25-24Upgrade TD Cowen Hold → Buy $156 → $175
May-31-24Initiated Stifel Buy $200
Dec-20-23Initiated Jefferies Buy $150
Jun-14-23Resumed Credit Suisse Neutral $89
Apr-05-23Downgrade Oppenheimer Outperform → Perform
Apr-04-23Downgrade Morgan Stanley Overweight → Equal-Weight $151 → $108
Apr-03-23Downgrade Credit Suisse Outperform → Neutral
Oct-20-22Initiated Goldman Buy $174
Aug-30-22Resumed Berenberg Buy $166
Nov-14-24 04:01PM
Nov-07-24 04:01PM
Nov-05-24 12:12PM
10:00AM
07:27AM
07:10AM Loading…
07:10AM
Nov-04-24 03:30PM
01:34PM
07:00AM
Oct-01-24 10:13AM
Sep-30-24 08:30AM
08:30AM
Sep-25-24 03:50PM
Sep-19-24 08:16PM
Sep-18-24 04:04PM
09:02AM Loading…
Sep-17-24 09:02AM
01:30AM
Sep-16-24 04:01PM
03:12PM
07:00AM
Sep-14-24 07:54PM
Sep-13-24 08:30AM
Sep-11-24 05:37PM
Sep-04-24 05:02PM
04:48PM
04:02PM
09:14AM
Sep-03-24 05:14PM
05:06PM
05:04PM
09:01AM Loading…
Sep-02-24 09:01AM
Aug-28-24 08:30AM
Aug-14-24 12:31PM
08:59AM
Aug-13-24 04:32AM
Aug-12-24 04:55PM
07:30AM
07:00AM
Jul-07-24 09:01AM
Jul-05-24 06:33AM
Jul-04-24 12:48PM
Jun-24-24 04:45PM
Jun-21-24 01:02AM
Jun-04-24 04:01PM
Jun-03-24 04:01PM
May-30-24 08:30AM
May-15-24 01:57PM
10:44AM
May-14-24 04:07PM
03:20PM
02:47PM
02:38PM
02:31PM
May-13-24 09:29AM
08:30AM
May-09-24 08:30AM
May-06-24 09:59AM
May-03-24 03:49AM
May-02-24 09:57PM
04:01PM
Apr-25-24 04:46PM
Apr-24-24 11:33AM
08:34AM
08:30AM
Apr-02-24 06:13AM
Mar-22-24 12:09PM
05:27AM
Mar-17-24 08:50AM
Mar-07-24 08:14AM
Mar-04-24 08:30AM
Feb-15-24 12:00PM
09:40AM
Feb-08-24 10:07AM
Feb-07-24 04:01PM
08:30AM
Feb-06-24 08:46AM
Jan-31-24 04:15PM
04:01PM
Jan-29-24 08:30AM
Jan-08-24 06:01PM
08:20AM
Jan-07-24 05:45PM
02:00PM
Dec-28-23 04:15PM
Dec-20-23 08:30AM
Dec-19-23 08:30AM
Dec-11-23 08:30AM
Nov-29-23 04:30AM
Nov-20-23 08:00AM
Nov-15-23 08:00AM
Nov-08-23 02:07PM
Nov-07-23 04:01PM
Nov-01-23 09:55AM
Oct-31-23 08:30AM
Oct-26-23 09:35AM
08:30AM
Oct-16-23 04:01PM
Oct-02-23 08:00AM
Sep-23-23 07:00AM
Sep-22-23 09:24AM
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JENSEN FLEMMING STEENOfficerDec 03 '24Proposed Sale131.379,3751,231,574Dec 03 04:35 PM
Hartvig Camilla HarderOfficerNov 19 '24Proposed Sale122.3819,4682,382,402Nov 19 04:08 PM